Pfizer's oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It might take a while longer, but Pfizer is on the path to ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

Pfizer (PFE) on Tuesday announced that a patient who was taking part in a long-term extension trial for its hemophilia therapy Hympavzi (marstacimab) died after serious adverse events. The patient ...

Pfizer stock has been a weak performer, declining by about 7% through 2025. Things could remain mixed over 2026 as well, with the company guiding for revenues of $59.5-$62.5 billion and adjusted EPS ...

Dec 23 (Reuters) - A patient who was being treated with Pfizer's (PFE.N), opens new tab hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders. The death occurred on Dec. 14 after the patient ...

The U.S. Food and Drug Administration (FDA) has approved a major safety update to the label of Depo-Provera, a widely used birth control injection. Nearly 2,000 women have filed lawsuits against ...

We may receive a commission on purchases made from links. A tablet is a great buy if you want the portability of a smartphone in a larger form factor. Whether you need a device that will be great for ...